To broadly examine the effects of WT RAS deletion in KRAS-mutated cancer cells, we performed a meta-analysis of mutated KRAS, WT HRAS, and WT NRAS dependencies in KRAS-mutated colorectal cancer, non-small cell lung cancer, and pancreatic cancer cell lines from both the Dependency Map Portal (DepMap) [51,52,53] and a large-scale siRNA knockdown screen that assessed RNAi depletion of RAS pathway ‘nodes’ (siRNEN Screen [54]). The gene discussed is HRAS; the disease is cancer.